BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Vaccines

Thermo Fisher Scientific Expands Sterile Drug Facility in Singapore, Strengthening Asia-Pacific BioPharma Market

Thermo Fisher Scientific, a global leader in serving science, announces the expansion of its sterile drug facility in Singapore, marking a significant mile...

June 02, 2023 | Influencers

Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers

87% of respondents deemed mRNA a key modality for the future More than 60% of vaccine makers surveyed plan revamp or new facilities for mRNA m...

June 01, 2023 | News

Immorna Initiates Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine

"The initiation of our FIH study with JCXH-105 is an important milestone for Immorna and for the development of a potential innovative vaccine for Shingles...

May 31, 2023 | News

Luzhu Biotechnology's LZ901 Completes Phase II Clinical Trial for Herpes Zoster Vaccine

Beijing Luzhu Biotechnology Co., Ltd. ("Luzhu Biotechnology" or the "Company", together with its subsidiaries, the "Group", stock code: 02480.HK), a l...

May 31, 2023 | News

SK Bioscience Proposes Vaccine Access Solution at World Economic Forum's Collaborative

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company's CE...

May 24, 2023 | News

Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region

Thermo Fisher Scientific, the world leader in serving science, has opened a new sterile drug facility in Singapore that will better enable customers to del...

May 19, 2023 | News

Novavax's COVID vaccine authorized for Singaporean adolescents.

"This news acknowledges the need to maintain access to a diverse COVID vaccine portfolio," said John C. Jacobs, President and Chief Executive Officer,...

May 15, 2023 | News

Novavax's COVID-Influenza Combo and High-dose COVID Vaccine Show Strong Immune Responses in Phase 2

This Phase 2 trial is evaluating three vaccine candidates: COVID-Influenza Combination, stand-alone influenza and high-dose COVID Preliminary topline im...

May 10, 2023 | News

Health Canal Survey: Why Older Adults are Hesitant to Receive the Bivalent Booster Shot

The CDC has recommended the bivalent mRNA COVID-19 vaccines since September 2022, yet only 42.4 percent of older adults have received the updated vacc...

May 02, 2023 | News

RNAimmune's RV-1730 COVID-19 booster vaccine receives FDA clearance for Phase 1 trial.

The proposed clinical study will involve in an evaluation of RV-1730 for its safety and prophylaxis efficacy against SARS-CoV-2 infection with people...

April 28, 2023 | News

Exothera Forms Partnership with Quantoom Biosciences to Launch RNA Business Unit

Exothera has partnered with Quantoom Biosciences ("Quantoom") to gain access to Quantoom’s Nfinity technology, a continuous production platform for R...

April 27, 2023 | News

Everest Medicines partners with Shanghai Pharma subsidiary to commercialize XERAVA in China

According to the MoU, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline) in China. SPH Kyuan'...

April 19, 2023 | News

Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses

"This collaboration represents an exciting opportunity for Nona Biosciences to leverage its fully human antibody H2L2 transgenic mice, together with the te...

April 19, 2023 | News

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer announced that Clev...

April 18, 2023 | News

Stay Connected